Objective measurement of cough in pulmonary fibrosis: A cohort study (ImpaCT)

Among patients with interstitial lung disease (ILD), cough is a prevalent symptom and can persist over time, with chronic cough having a major impact on patients' quality of life [1–3]. Moreover, it has been hypothesised that cough may enhance fibrotic remodelling via cough-induced mechanical stress [1, 4]. However, while persistent cough is commonly reported in idiopathic pulmonary fibrosis (IPF) and is associated with worse prognosis [1, 3, 5], data are limited on the impact of cough in patients with pulmonary fibrosis other than IPF [2, 5]. This study aimed to assess the frequency and distribution of cough during the daytime and night-time in patients with pulmonary fibrosis other than IPF using objective cough monitoring, as well as patient-reported severity and impact of cough. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of interest: JK reports research contracts with Boehringer Ingelheim, CSL Behring, United Therapeutics, Genentech, Insilico and ATYR Pharma. Conflict of interest: SPH reports grants or contracts with Boehringer Ingelheim, consulting fees from Trevi Therapeutics, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim and Chiesi, support for attending meetings and/or travel from Boehringer Ingelheim, Chiesi and Trevi Therapeutics, and is a trustee for Action for Pulmonary Fibrosis. Conflict of interest: RJK reports institutional grants or contacts with National Institutes of Health, Boehringer Ingelheim, Chiesi, CSL Behring, Genentech, Respivant, Toray, Bellerophon and US Department of Defense, personal royalties or licences from UpToDate, personal payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Genentech, Vindico and France Foundation, support for attending meetings and/or travel from United Therapeutics and Boehringer Ingelheim, participation on a data safety monitoring board or advisory board for PureTech, Pliant, Boehringer Ingelheim, Genentech, United Therapeutics, Verona Pharma, Galapagos (Endpoint Adjudication Committee), AstraZeneca (Endpoint Adjudication Committee), unpaid leadership or fiduciary roles with Pulmonary Wellness Foundation and Stony Wold Foundation, personal stock or stock options with Doximity and Air Cycle Systems, and receipt of medical writing support from Boehringer Ingelheim, Genentech, Galapagos and AstraZeneca. Conflict of interest: TK reports consulting fees from Boehringer Ingelheim Inc, Puretech Inc, United Therapeutics Corp and Aileron Inc, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim Inc and Veracyte, and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim Inc and Puretech Inc. LW, CC, RV and NP are employees of Boehringer Ingelheim. MSW reports institutional grants or contracts with The Netherlands Organisation for Health Research and Development, The Dutch Lung Foundation, The Dutch Pulmonary Fibrosis organization, Sarcoidosis.nl, Boehringer Ingelheim, Hoffmann-La Roche and AstraZeneca-Daiichi, consulting fees paid to their institution from AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Galecto, GSK, Hoffmann-La Roche, Horizon therapeutics, Kinevant Sciences, Molecure, Nerre Therapeutics, Novartis, PureTech Health, Thyron, Trevi and Vicore, payment or honoraria to their institution for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, CSL Behring, Hoffmann-La Roche and Novartis, support for attending meetings and/or travel from Boehringer Ingelheim, GSK, Hoffmann-La Roche and Galapagos, and leadership or fiduciary roles as Chair of the Idiopathic Interstitial Pneumonia group of the European Respiratory Society, member of the board of the Netherlands Respiratory Society, member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and related disorders federation, Chair of the educational committee of the European Reference Network for Rare Lung Diseases and member of an advisory board of the Dutch Lung-fibrosis and Sarcoidosis Patient Associations.